10x Genomics Inc(TXG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.59 | Insider Own | 10.85% | Shs Outstand | 120.2M | Perf Week | 9.18% |
| Market Cap | 10.17B | Forward P/E | - | EPS next Y | 3.46% | Insider Trans | -1.93% | Shs Float | 116.2M | Perf Month | -11.84% |
| Enterprise Value | 9.69B | PEG | - | EPS next Q | -0.27 | Inst Own | 103.59% | Short Float | 10.96% | Perf Quarter | 68.44% |
| Income | -0.08B | P/S | 16.48 | EPS this Y | -113.17% | Inst Trans | 5.83% | Short Ratio | 3.83 | Perf Half Y | 265.09% |
| Sales | 0.62B | P/B | 12.31 | EPS next 5Y | -6.91% | ROA | -7.47% | Short Interest | 12.73M | Perf YTD | 378.36% |
| Book/sh | 6.34 | P/C | 18.41 | EPS past 3/5Y | 37.9% 42.1% | ROE | -9.4% | 52W High | -24.11% ($102.81) | Perf Year | 474.1% |
| Cash/sh | 4.24 | P/FCF | 83.71 | Sales past 3/5Y | 7.57% 16.55% | ROIC | -8.42% | 52W Low | 532.25% ($12.34) | Perf 3Y | 114.28% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.82% | Gross Margin | 70.58% | Volatility(W/M) | 8.86% 9.19% | Perf 5Y | -50.91% |
| Dividend TTM | - | EV/Sales | 15.71 | Sales Y/Y TTM | -4.28% | Oper. Margin | -14.12% | ATR (14) | 6.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.25 | EPS Q/Q | -149.75% | Profit Margin | -12.18% | RSI (14) | 53.85 | Recom | 2.41 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.69 | Sales Q/Q | -12.65% | SMA20 | 0.24% ($77.83) | Beta | 2.01 | Target Price | $77.5 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/5 | SMA50 | 6.73% ($73.1) | Rel Volume | 0.64 | Prev Close | $72.96 |
| Employees | 1178 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 42.41% 2.97% | SMA200 | 96.51% ($39.7) | Avg Volume(3M) | 3.32M | Price | $78.02 |
| IPO | 2019/9/12 | Option/Short | Yes/Yes | Trades | 24695 | Volume | 2,129,171 | Change | 6.94% |
🧬 A life sciences technology company that provides tools for single-cell and spatial genomics analysis. It supplies instruments, consumables, and software for single-cell and spatial biology research, which are used by research institutions and pharmaceutical companies for precision biology studies. A leading company in the single-cell and spatial analysis field.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
Next earnings report: November 5
8 days to go.
TXG has a sound balance sheet but weak earning power
Of every $100 in sales, $14.12 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -113.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,648. Peers typically go for $254.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -50.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #17 of 142 in the industry
Based on market cap of $10B.
GMED#13 Globus Medical Inc $11B PER 20.7 
GKOS#14 Glaukos Corp $11B PER - 
PODD#15 Insulet Corp $10B PER 29.7 
BIO#16 Bio-Rad Laboratories Inc $10B PER 46.2 TXG#17 10x Genomics Inc $10B PER - 
FAQ
What kind of company is TXG?
TXG belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TXG?
The market cap of TXG is approximately $10.2B, ranking 918 within its sector.
What is the 52-week high and low for TXG?
TXG has recorded a 52-week high of $102.81 and a low of $12.34.
